Drug
Odronextamab
Odronextamab: highest development phase Phase 3, developed by Regeneron. 1 trial record tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Regeneron
Trials
| Drug | Phase | Indication |
|---|---|---|
| Odronextamab NCT06230224 | Phase 3 | B-Cell Non-Hodgkin Lymphoma (B-NHL) |
Latest
No recent events.
Follow Odronextamab on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.